Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 5/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.41 |
| ▸ | GNRHR | P30968 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | MLNR | O43193 | 2/20 | 0.41 |
| ▸ | GMNN | O75496 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780829 | 0.92 | GABRA5 (0.45) | GRIN1GRIN2BMEN1KMT2AGABRA5 | |
| SCHEMBL4285362 | 0.83 | CYP19A1 (0.42) | GRIN1GRIN2BMEN1KMT2ALMNA | |
| SCHEMBL4281542 | 0.81 | LMNA (0.47) | GRIN1GRIN2BGABRA5GABRA1GNRHR | |
| SCHEMBL4283324 | 0.78 | LMNA (0.44) | MEN1KMT2ALMNAOPRM1MLNR | |
| SCHEMBL4752716 | 0.77 | DRD3 (0.57) | MEN1KMT2ALMNAOPRM1MLNR | |
| SCHEMBL4288888 | 0.76 | LMNA (0.43) | MEN1KMT2ALMNAOPRM1MLNR | |
| SCHEMBL4281572 | 0.75 | MEN1 (0.42) | MEN1KMT2ALMNAOPRM1MLNR | |
| SCHEMBL8233262 | 0.75 | MEN1 (0.42) | MEN1KMT2ALMNAOPRM1MLNR | |
| SCHEMBL4284927 | 0.75 | SCN5A (0.58) | MEN1KMT2ALMNAOPRM1MLNR | |
| SCHEMBL7265242 | 0.73 | GABRA5 (0.46) | GRIN1GRIN2BGABRA5GABRA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | claimed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | claimed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1987009-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | GRIN1 337/4885GRIN2B 393/4885MEN1 2184/4885 |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | GRIN1 337/4885GRIN2B 393/4885MEN1 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.